TY - JOUR
T1 - Impact of Massive or Torrential Tricuspid Regurgitation in Patients Undergoing Transcatheter Tricuspid Valve Intervention
AU - TriValve Investigators
AU - Miura, Mizuki
AU - Alessandrini, Hannes
AU - Alkhodair, Abdullah
AU - Attinger-Toller, Adrian
AU - Biasco, Luigi
AU - Lurz, Philipp
AU - Braun, Daniel
AU - Brochet, Eric
AU - Connelly, Kim A.
AU - de Bruijn, Sabine
AU - Denti, Paolo
AU - Deuschl, Florian
AU - Estevez-Loureiro, Rodrigo
AU - Fam, Neil
AU - Frerker, Christian
AU - Gavazzoni, Mara
AU - Hausleiter, Jörg
AU - Himbert, Dominique
AU - Ho, Edwin
AU - Juliard, Jean Michel
AU - Kaple, Ryan
AU - Besler, Christian
AU - Kodali, Susheel
AU - Kreidel, Felix
AU - Kuck, Karl Heinz
AU - Latib, Azeem
AU - Lauten, Alexander
AU - Monivas, Vanessa
AU - Mehr, Michael
AU - Muntané-Carol, Guillem
AU - Nazif, Tamin
AU - Nickenig, Georg
AU - Pedrazzini, Giovanni
AU - Philippon, François
AU - Pozzoli, Alberto
AU - Praz, Fabien
AU - Puri, Rishi
AU - Rodés-Cabau, Josep
AU - Schäfer, Ulrich
AU - Schofer, Joachim
AU - Sievert, Horst
AU - Tang, Gilbert H.L.
AU - Thiele, Holger
AU - Rommel, Karl Philipp
AU - Vahanian, Alec
AU - Von Bardeleben, Ralph Stephan
AU - Webb, John G.
AU - Weber, Marcel
AU - Windecker, Stephan
AU - Winkel, Mirjam
N1 - Funding Information:
Dr. Miura has been a consultant for Japan Lifeline. Dr. Lurz has received speaker fees from Abbott. Dr. Braun has received speaker honoraria and travel support from Abbott Vascular. Dr. Brochet has received speaker fees from Abbott Vascular. Dr. Denti has served as a consultant for Abbott Vascular, 4Tech Cardio, Neovasc, and InnovHeart; and has received honoraria from Abbott. Dr. Deuschl has served as a proctor and consultant for Valtech/Edwards Lifesciences and Neovasc; has received speaker honoraria from Abbott; and has received unrestricted travel grants from Boston Scientific, Abbott, Edwards Lifesciences, and Neovasc. Dr. Estevez-Loureiro has received research support from Abbott; and is a consultant for Abbott and Boston Scientific. Dr. Hausleiter has received speaker honoraria from Abbott Vascular and Edwards Lifesciences. Dr. Himbert has served as a proctor and consultant for Edwards Lifesciences. Dr. Kodali is a consultant for Claret Medical, Abbott Vascular, Meril Lifesciences, and Admedus; and holds equity in Thubrikar Aortic Valve, Dura Biotech, BioTrace Medical, and MID. Dr. Kreidel has received speaker honoraria and consulting fees from Abbott and Edwards Lifesciences. Dr. Kuck has served as a consultant for Abbott Vascular, St. Jude Medical, Biotronik, Medtronic, Biosense Webster, Boston Scientific, Edwards Lifesciences, and Mitralign; and is a cofounder of Cardiac Implants. Dr. Latib has served on the advisory board for Medtronic and Abbott Vascular; has served on the Speakers Bureau for Abbott Vascular; has served on the scientific advisory board for Millipede; and has served as a consultant for 4Tech Cardio, Mitralign, and Millipede. Dr. Lauten has received research support from Abbott and Edwards Lifesciences; and has been a consultant to Abbott, Edwards Lifesciences, and TricValve. Dr. Mehr has received a travel grant from Bristol-Myers Squibb. Dr. Nazif has been a consultant to Edwards Lifesciences, Boston Scientific, and Medtronic. Dr. Praz has been a consultant to Edwards Lifesciences. Dr. Rodés-Cabau has received institutional research grants from Edwards Lifesciences. Dr. Schäfer has received lecture fees, study honoraria, and travel expenses from Abbott; and has been a member of an advisory board for Abbott. Prof. Sievert has received study honoraria, travel expenses, and consulting fees from 4Tech Cardio, Abbott, Ablative Solutions, Ancora Heart, Bavaria Medizin Technologie, BioVentrix, Boston Scientific, Carag, Cardiac Dimensions, CeloNova Biosciences, Comed, Contego, CVRx, Edwards Lifesciences, Endologix, Hemoteq, Lifetech, Maquet Getinge Group, Medtronic, Mitralign, Nuomao Medtech, Occlutech, pfm Medical, ReCor Medical, Renal Guard, Rox Medical, Terumo, Vascular Dynamics, and Vivasure Medical. Dr. Tang has served as a consultant, an advisory board member, and a faculty trainer for Abbott Structural Heart. Dr. Vahanian has served as a consultant for Abbott Vascular, Edwards Lifesciences, and MitralTech; and has received speaker fees from Abbott Vascular and Edwards Lifesciences. Dr. Webb has received research support from Edwards Lifesciences; and has served as a consultant for Abbott Vascular, Edwards Lifesciences, and St. Jude Medical. Dr. Windecker has received institutional research grants from Abbott, Amgen, Boston Scientific, Biotronik, Edwards Lifesciences, Medtronic, St. Jude Medical, and Terumo. Dr. Zuber is a consultant for Abbott and Edwards Lifesciences. Dr. Leon has served as a nonpaid member of the scientific advisory board of Edwards Lifesciences; and has been a consultant to Abbott Vascular and Boston Scientific. Dr. Maisano has received grant and/or research support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, NVT, and Terumo; has received consulting fees and honoraria from Abbott, Medtronic, Edwards Lifesciences, Perifect, Xeltis, Transseptal Solutions, Cardiovalve, and Magenta; has royalty income and intellectual property rights from Edwards Lifesciences; and is a shareholder in Cardiovalve, Magenta, Transseptal Solutions, 4Tech Cardio, and Perifect. Dr. Hahn has served as a consultant for Abbott Vascular, NaviGate, and GE Healthcare. Dr. Taramasso is a consultant for Abbott Vascular, Boston Scientific, 4Tech Cardio, and CoreMedic; and has received speaker honoraria from Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2020 American College of Cardiology Foundation
PY - 2020/9/14
Y1 - 2020/9/14
N2 - Objectives: The aim of this study was to assess the clinical outcome of baseline massive or torrential tricuspid regurgitation (TR) after transcatheter tricuspid valve intervention (TTVI). Background: The use of TTVI to treat symptomatic severe TR has been increasing rapidly, but little is known regarding the impact of massive or torrential TR beyond severe TR. Methods: The study population comprised 333 patients with significant symptomatic TR from the TriValve Registry who underwent TTVI. Mid-term outcomes after TTVI were assessed according to the presence of massive or torrential TR, defined as vena contracta width ≥14 mm. Procedural success was defined as patient survival after successful device implantation and delivery system retrieval, with residual TR ≤2+. The primary endpoint comprised survival rate and freedom from rehospitalization for heart failure, survival rate, and rehospitalization at 1 year. Results: Baseline massive or torrential TR and severe TR were observed in 154 patients (46.2%) and 179 patients (53.8%), respectively. Patients with massive or torrential TR had a higher prevalence of ascites than those with severe TR (27.3% vs. 20.4%, respectively; p = 0.15) and demonstrated a similar procedural success rate (83.2% vs. 77.3%, respectively; p = 0.21). The incidence of peri-procedural adverse events was low, with no significant between-group differences. Freedom from the composite endpoint was significantly lower in patients with massive or torrential TR than in those with severe TR, which was significantly associated with an increased risk for 1-year death of any cause or rehospitalization for heart failure (adjusted hazard ratio: 1.91; 95% confidence interval: 1.10 to 3.34; p = 0.022). Freedom from the composite endpoint was significantly higher in patients with massive or torrential TR when procedural success was achieved (69.9% vs. 54.2%, p = 0.048). Conclusions: Baseline massive or torrential TR is associated with an increased risk for all-cause mortality and rehospitalization for heart failure 1 year after TTVI. Procedural success is related to better outcomes, even in the presence of baseline massive or torrential TR.
AB - Objectives: The aim of this study was to assess the clinical outcome of baseline massive or torrential tricuspid regurgitation (TR) after transcatheter tricuspid valve intervention (TTVI). Background: The use of TTVI to treat symptomatic severe TR has been increasing rapidly, but little is known regarding the impact of massive or torrential TR beyond severe TR. Methods: The study population comprised 333 patients with significant symptomatic TR from the TriValve Registry who underwent TTVI. Mid-term outcomes after TTVI were assessed according to the presence of massive or torrential TR, defined as vena contracta width ≥14 mm. Procedural success was defined as patient survival after successful device implantation and delivery system retrieval, with residual TR ≤2+. The primary endpoint comprised survival rate and freedom from rehospitalization for heart failure, survival rate, and rehospitalization at 1 year. Results: Baseline massive or torrential TR and severe TR were observed in 154 patients (46.2%) and 179 patients (53.8%), respectively. Patients with massive or torrential TR had a higher prevalence of ascites than those with severe TR (27.3% vs. 20.4%, respectively; p = 0.15) and demonstrated a similar procedural success rate (83.2% vs. 77.3%, respectively; p = 0.21). The incidence of peri-procedural adverse events was low, with no significant between-group differences. Freedom from the composite endpoint was significantly lower in patients with massive or torrential TR than in those with severe TR, which was significantly associated with an increased risk for 1-year death of any cause or rehospitalization for heart failure (adjusted hazard ratio: 1.91; 95% confidence interval: 1.10 to 3.34; p = 0.022). Freedom from the composite endpoint was significantly higher in patients with massive or torrential TR when procedural success was achieved (69.9% vs. 54.2%, p = 0.048). Conclusions: Baseline massive or torrential TR is associated with an increased risk for all-cause mortality and rehospitalization for heart failure 1 year after TTVI. Procedural success is related to better outcomes, even in the presence of baseline massive or torrential TR.
KW - transcatheter tricuspid valve intervention
KW - tricuspid regurgitation
KW - tricuspid valve
UR - http://www.scopus.com/inward/record.url?scp=85089936043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089936043&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2020.05.011
DO - 10.1016/j.jcin.2020.05.011
M3 - Article
C2 - 32912460
AN - SCOPUS:85089936043
SN - 1936-8798
VL - 13
SP - 1999
EP - 2009
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 17
ER -